{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "29028957",
  "DateCompleted": {
    "Year": "2019",
    "Month": "10",
    "Day": "24"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "04",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1093/cid/cix870"
    ],
    "Journal": {
      "ISSN": "1537-6591",
      "JournalIssue": {
        "Volume": "66",
        "Issue": "7",
        "PubDate": {
          "Year": "2018",
          "Month": "Mar",
          "Day": "19"
        }
      },
      "Title": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",
      "ISOAbbreviation": "Clin Infect Dis"
    },
    "ArticleTitle": "Long-term Mortality and Disability in Cryptococcal Meningitis: A Systematic Literature Review.",
    "Pagination": {
      "StartPage": "1122",
      "EndPage": "1132",
      "MedlinePgn": "1122-1132"
    },
    "Abstract": {
      "AbstractText": [
        "Cryptococcal meningitis (CM) is the primary cause of meningitis in adults with human immunodeficiency virus (HIV) infection and an emerging disease in HIV-seronegative individuals. No literature review has studied the long-term outcome of CM. We performed a systematic review on the long-term (\u22653-month) impact of CM (Cryptococcus neoformans and Cryptococcus gattii) on mortality and disability in HIV-infected and non-HIV-infected adults. Although the quality of current evidence is limited, the long-term impact of CM on survival and disability seems to be high. One-year mortality ranged from 13% in an Australian non-HIV-infected C. gattii-infected cohort to 78% in a Malawian HIV-infected cohort treated with fluconazole monotherapy. One-year impairment proportions among survivors ranged from 19% in an Australian C. gattii cohort to >70% in a Taiwanese non-HIV- and HIV-infected cohorts. Ongoing early therapeutic interventions, early detection of impairments and access to rehabilitation services may significantly improve patients' survival and quality of life."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "London School of Hygiene and Tropical Medicine, Faculty of Public Health and Policy, United Kingdom."
          }
        ],
        "LastName": "Pasquier",
        "ForeName": "Estelle",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "London School of Hygiene and Tropical Medicine, Faculty of Public Health and Policy, United Kingdom."
          }
        ],
        "LastName": "Kunda",
        "ForeName": "John",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre Population et D\u00e9veloppement - UMR 196 - Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale U1244, Institut de Recherche pour le D\u00e9veloppement (IRD), Paris Descartes University, France."
          }
        ],
        "LastName": "De Beaudrap",
        "ForeName": "Pierre",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre for Global Health, Institute for Infection and Immunity, St. George's University of London, United Kingdom."
          }
        ],
        "LastName": "Loyse",
        "ForeName": "Angela",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institut Pasteur, Molecular Mycology Unit, National Reference Center for Invasive Mycoses & Antifungals, Centre National de la Recherche Scientifique, Paris."
          }
        ],
        "LastName": "Temfack",
        "ForeName": "Elvis",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre for Global Health, Institute for Infection and Immunity, St. George's University of London, United Kingdom."
          }
        ],
        "LastName": "Molloy",
        "ForeName": "S\u00edle F",
        "Initials": "SF"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Centre for Global Health, Institute for Infection and Immunity, St. George's University of London, United Kingdom."
          }
        ],
        "LastName": "Harrison",
        "ForeName": "Thomas S",
        "Initials": "TS"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institut Pasteur, Molecular Mycology Unit, National Reference Center for Invasive Mycoses & Antifungals, Centre National de la Recherche Scientifique, Paris."
          },
          {
            "Identifier": [],
            "Affiliation": "Paris Descartes University, Assistance Publique - H\u00f4pitaux de Paris (APHP), Necker Pasteur Center for Infectious Diseases and Tropical Medicine, Institut Hospitalo-Universitaire (IHU) Imagine, Necker Enfants Malades Hospital, France."
          }
        ],
        "LastName": "Lortholary",
        "ForeName": "Olivier",
        "Initials": "O"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Systematic Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Clin Infect Dis",
    "NlmUniqueID": "9203213",
    "ISSNLinking": "1058-4838"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antifungal Agents"
    },
    {
      "RegistryNumber": "8VZV102JFY",
      "NameOfSubstance": "Fluconazole"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antifungal Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Australia"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cryptococcus gattii"
    },
    {
      "QualifierName": [
        "pathogenicity"
      ],
      "DescriptorName": "Cryptococcus neoformans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disabled Persons"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Fluconazole"
    },
    {
      "QualifierName": [
        "complications",
        "microbiology"
      ],
      "DescriptorName": "HIV Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy",
        "mortality"
      ],
      "DescriptorName": "Meningitis, Cryptococcal"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Quality of Life"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Randomized Controlled Trials as Topic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    }
  ]
}